Krebs Biochemicals & Industries Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Krebs Biochemicals & Industries Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 2.2 times its market value (net debt). Lower than almost all Healthcare companies in India.
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ₹128 per ₹100 of sales comes from others' credit, against ₹25 from others' credit three years earlier. Less money tied up than almost all Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 95% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 95% of Healthcare companies in India.
Cash Locked Ratio
−₹128Money owed to suppliers is larger than money owed by customers plus stock: ₹128 per ₹100 of sales comes from others' credit, against ₹25 from others' credit three years earlier.
Less money tied up than almost all Healthcare companies in India.
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 54%
Sales fell 54% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-54% / -7%In 3 years sales changed by -54% while total assets changed by -7%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-0.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 90% of Healthcare companies in India.
Cash Cushion Ratio
2.2× debtDebt, after subtracting cash, is 2.2 times its market value (net debt).
Lower than almost all Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 74% of Healthcare companies in India.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Krebs Biochemicals & Industries Limited made a loss over the last year. Krebs Biochemicals & Industries Limited owes ₹2.00 for every ₹1 it owns. Krebs Biochemicals & Industries Limited made a loss in each of the last two years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossKrebs Biochemicals & Industries Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.76Krebs Biochemicals & Industries Limited's book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
₹124 CrThe total market value of all of Krebs Biochemicals & Industries Limited's shares at today's price (share price × number of shares), smaller than 97% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeKrebs Biochemicals & Industries Limited's net worth is negative (₹163 Cr below zero, balance sheet 31 Mar 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
2.00×Krebs Biochemicals & Industries Limited owes ₹2.00 for every ₹1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in India.
Dividend yield
NoneKrebs Biochemicals & Industries Limited does not currently pay a dividend.
Revenue growth
-45%Revenue fell 45% in the year to Mar 2026, and shrank 23% a year on average over 3 years.
Profit growth
LossKrebs Biochemicals & Industries Limited made a loss in each of the last two years.
Profit margin
-71.4%Krebs Biochemicals & Industries Limited lost ₹71 for every ₹100 of revenue.
Interest cover
Not coveredKrebs Biochemicals & Industries Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net debtKrebs Biochemicals & Industries Limited had ₹270 Cr more debt than cash (net debt) at Mar 2026.
Questions
How much does Krebs Biochemicals & Industries Limited owe compared with what it owns?
Krebs Biochemicals & Industries Limited owes ₹2.00 for every ₹1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in India.
Does Krebs Biochemicals & Industries Limited pay a dividend?
No. Krebs Biochemicals & Industries Limited does not currently pay a dividend.
Is Krebs Biochemicals & Industries Limited's revenue growing?
Revenue fell 45% in the year to Mar 2026, and shrank 23% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.